to improve shared decision-making between patients and physicians. However, there is limited research on the relevancies of the numerous available PROs to patients with PDAC and whether these align with what their physicians believe are patient
Search Results
Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar
Terrell Johnson, Lindsey A.M. Bandini, Darryl Mitteldorf, Elizabeth Franklin, Justin E. Bekelman, and Robert W. Carlson
’ve lost the ability to listen to patients, to capture the patient voice,” stated Dr. Bekelman, “There’s a serious disconnect.” To enhance providers’ ability to engage in shared decision-making interventions, it is essential that oncology practices make
Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins
highlight the need for improved physician-patient communication during the clinical encounter to inform the treatment plan. A shared decision-making process has been advocated to improve patient perceptions of the quality of the care experience and to
Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson
randomized clinical trials given the short duration of follow-up relative to the long latency to incident late effects. Simulation models offer one avenue for estimating an individual’s risk for a given late effect and can be integrated into shared decision-making
Maxwell T. Vergo and Al B. Benson III
absolute benefits patients may expect from adjuvant therapy in their situation. This can be weighed against known long-term adverse effects from receiving adjuvant chemotherapy, optimizing the shared decision-making process between patient and physician
Andrew T. Kuykendall and Rami Komrokji
routinely recommend cytoreductive therapy; however, this is another situation in which shared decision-making is vital. Broadly speaking, the lack of consensus regarding the impact of platelet count in ET suggests this is a complex relationship that is
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
-making occurs for patients with resectable PDAC and whether specific barriers to the use of NT exist. Further data on patient and physician preferences and the patient experience during NT may highlight opportunities to improve shared decision-making and
Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico, and Mark F. Berry
-negative NSCLC in a nontrial setting, which can improve the shared decision-making process and better inform treatment recommendations. In this study, 900 patients aged 70 years or older were given AC. Although there are no specific guidelines for the treatment
Julia T. van Groningen, Pieter van Hagen, Rob A.E.M. Tollenaar, Jurriaan B. Tuynman, Perla J. Marang-van de Mheen, Pascal G. Doornebosch, Pieter J. Tanis, Eelco J.R. de Graaf, and on behalf of the Dutch Colorectal Audit
and performance of cTME after neoadjuvant therapy. When discussing treatment options with an individual patient after local excision, shared decision-making may lead to refraining from cTME. Several factors may contribute to this: first, patient
Peter D. Stetson, Nadine J. McCleary, Travis Osterman, Kavitha Ramchandran, Amye Tevaarwerk, Tracy Wong, Jessica M. Sugalski, Wallace Akerley, Annette Mercurio, Finly J. Zachariah, Jonathan Yamzon, Robert C. Stillman, Peter E. Gabriel, Tricia Heinrichs, Kathleen Kerrigan, Shiven B. Patel, Scott M. Gilbert, and Everett Weiss
, including whether it is used to facilitate shared decision-making between providers and patients. We also did not obtain the technical or operational specifics regarding how those centers that have had the most success with PGHD integration have accomplished
